Diffuse Intrinsic Pontine Glioma Clinical Trials in Seattle, Washington

9 studies are recruiting for diffuse intrinsic pontine glioma in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

2. Study of Olutasidenib and Temozolomide in HGG

   The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozol…

   Stage

   Phase 2

   Ages

   12 to 39

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   20 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT06161974 on ClinicalTrials.gov

3. PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

   This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a v…

   Stage

   Phase 2

   Ages

   3 to 39

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   13 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05096481 on ClinicalTrials.gov

4. Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

   This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient'…

   Stage

   Phase 2

   Ages

   1 to 26

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   6 in total

   Run by

   BrainChild Bio, Inc

   See if you can join NCT07680439 on ClinicalTrials.gov

5. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

6. Combination Therapy for the Treatment of Diffuse Midline Gliomas

   This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment opt…

   Stage

   Phase 2

   Ages

   2 to 39

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   32 in total

   Run by

   University of California, San Francisco

   See if you can join NCT05009992 on ClinicalTrials.gov

7. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

   The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

   Stage

   Phase 2

   Ages

   1 to 39

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   20 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05843253 on ClinicalTrials.gov

8. Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

   This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cav…

   Stage

   Phase 1

   Ages

   1 to 26

   Site

   Seattle Children's Hospital, Seattle, Washington

   Run by

   Seattle Children's Hospital

   See if you can join NCT04185038 on ClinicalTrials.gov

9. A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

   This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with …

   Stage

   EARLY_Phase 1

   Ages

   Up to 21

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   21 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT04655404 on ClinicalTrials.gov